Review on FKBP5, with data on DNA/RNA, on the protein encoded and where the gene is implicated.
DNA/RNA
Description FKBP5 gene is located on short arm of chromosome 6 (6p21.31). FKBP5 gene ranges from 35541362 to 35696360 on reverse strand with a total length of 154999 bp including 10 coding exons.
Transcription
This gene has been found to have multiple polyadenylation sites. Transcription of FKBP5 gene produces 4 different transcript variants due to alternative splicing (RefSeq, Mar 2009) . NM_004117 is the transcript most widely referred to, and its mRNA is 3803 bp long.
Protein

Note
Protein name: FK506 binding protein 51, FKBP51, Peptidyl-prolyl cis-trans isomerase (PPIase). It is encoded by the FKBP5 gene (Nair et al., 1997) .
Description
FKBP51 is a member of immunophilin family, proteins characterized by their ability to bind immunosuppresive drugs. Additionally, immunophilins are peptidylprolyl isomerases (PPIase) that catalyze the cis-trans conversion of peptidylprolyl bonds, a reaction important for protein folding (Fischer et al., 1984) . Sinars et al. (Sinars et al., 2003) initially showed the structure of FKBP51 and the orientation of its domains. The Nterminal domain, FK1, is an active rotamase domain (peptidyl-prolyl isomerase; PPIase) which is required to bind immunosuppressive drugs, such as FK506 (tacrolimus). In addition, it is responsible for binding to the kinase Akt (Pei et al., 2009) . The FK2 domain, needed for interaction with some binding partners (Figure 2 ), does not show measurable PPIase activity. The TRP domain consists of three highly degenerate 34 amino acid repeats TPR repeats, and is responsible for multiple protein-protein interactions (figure 2), for example with Hsp90 , progesterone receptor (PR) (Barent et al., 1998) , PH domain and leucine rich repeat protein phosphatase (PHLPP) (Pei et al., 2009 ). Up to date it has been established that FKBP5 expression is regulated by glucocorticoids, progestins, and androgens (Hubler et al., 2003; Hubler and Scammell, 2004; Makkonen et al., 2009; Paakinaho et al., 2010) .
Localisation
FKBP5 localizes to cytoplasm and nucleus.
Function
FKBP5 plays multiple important roles in cellular process. Since it has peptidyl-prolyl isomerase (PPIase) activity, it regulates protein folding (Galat, 1993; Fruman et al., 1994) . In addition, FKBP5 can associate with chaperones, thus playing a role in cell trafficking (Schiene-Fischer and Yu, 2001) . Also, it influences steroid receptor signaling (Denny et al., 2000; Barent et al., 1998; Ni et al., 2010) , NFκB pathway (Bouwmeester et al., 2004) , as well as Akt pathway (Pei et al., 2009) . Moreover, FKBP5 plays a role in regulating drug responses (Jiang et al., 2008; Li et al., 2008; Hou and Wang, 2012; Binder et al., 2004) .
Mutations
Note Next Generation resequencing of FKBP5 gene was performed using 96 Caucasian American samples and identified 657 single nucleotide polymorphisms (SNPs) (Ellsworth et al., 2013b) . In addition, Next Generation resequencing was also performed using 60 samples from pancreatic cancer patients and identified 404 SNPs (Ellsworth et al., 2013a) . All of these polymorphisms are germinal SNPs. 
Somatic
It has been reported that four confirmed somatic mutations in various cancer tissues has been identified (V37V: silent (ovary) M97I: missense (breast) (Cancer Genome Atlas Research Network, 2011), Y113Y: silent (pancreas) (Biankin et al., 2012) , S309L: missense (endometrium, lung, large intestine) (Liu et al., 2012) .
Implicated in
Cancer and response to chemotherapy Note FKBP51 is an important protein involved in the regulation of many key signaling cascades in the cell, such as Akt (Pei et al., 2009 ), NFκB (Bouwmeester et al., 2004 , and androgen receptor pathways (Ni et al., 2010) . All of these signalling pathways are implicated in tumorigenesis and response to drug treatment. It has been suggested that the contribution of FKBP5 in tumorgenesis and antineoplastic therapy is tissue-specific. Depending on the cellular context, FKBP5 can either promote or inhibit tumor progression and chemoresistance.
Pancreatic cancer
Note
The Akt pathway is one of the most important signaling pathways, playing a role in regulation of many cellular processes, including cell proliferation, growth, and other processes that crucial for cell survival (Manning and Cantley, 2007) . Akt is a serine/threonine kinase that in order to become fully activated needs its residues: Ser473 and Thr308 to be phosphorylated. This is facilitated by phosphoinositide 3-kinase (PIP3), as well as PDK1, and mTOR complex 2 (Alessi et al., 1996; Engelman et al., 2006; Sarbassov et al., 2005) . Conversely, phosphatases, such as PP2 holoenzymes and PHLPP de-phosphorylate Akt, halting its activity (Brognard et al., 2007; Carracedo and Pandolfi, 2008; Gao et al., 2005; Padmanabhan et al., 2009 ). The balance in phosphorylation levels of Akt determines its pathway activity, therefore affecting all the downstream cellular events. If Akt pathway becomes highly up-regulated, it potentially could lead to tumor development, progression and eventually to chemotherapy resistance (Pei et al., 2010) . Genome-wide association studies of cytidine analogues identified FKBP5 low expression levels to be associated with resistance to many chemotherapeutic drugs (Li et al., 2008; Pei et al., 2009) . Functional studies of FKBP5 demonstrated that FKBP51 acts as a scaffolding protein increasing interaction between Akt's phosphatase -PHLPP and Akt, thus decreasing the phosphorylation of Akt-Ser473 (Pei et al., 2009) . It was shown, that in pancreatic and breast cancer cells FKBP5 expression levels are decreased, while the phosphorylation of Akt-Ser473 is increased, which could lead to chemoresistance. Also, it suggested that FKBP5 might function as a tumor suppressor gene through the down-regulation of Akt activation (Pei et al., 2009, Hou and .
Acute lymphoblastic leukemia, glioma, melanoma
Note FKBP5 plays a pivotal role in regulating NF-κB pathway (Bouwmeester et al., 2004) . Specifically, FKBP51 interacts with several members of the NF-κB pathway including inhibitors of NF-κB kinase: IKKα, IKKε, TAK1 and MEKK1. It was shown, that FKBP51 enzymatic activity is required for IKK activation, which suggested that FKBP5 plays an important role in this pathway. Avellino et al. demonstrated , that the addition of rapamycin, a known inhibitor of FKBP51 enzymatic (PPIase) activity, to anthracycline treatment of blasts from chronic childhood acute lymphoblastic leukemia (ALL) patients would sensitize these cells to anthracyclines (Avellino et al., 2005) . These experiments suggested that the combination treatment of rapamycin and doxorubicin inhibits the activation of the NF-κB pathway, which leads to an increase in apoptosis, and, in turn, an increase in sensitivity to chemotherapy (Avellino et al., 2005) . Since NF-κB pathway activation leads to antiapoptotic signals, therefore, in this case, FKBP5 plays a role in chemoresistance to drugs such as anthracyclines. In addition, in glioma cells, FKBP5 expression contributes to glioma cells growth and sensitivity to rapamycin through regulation of the NF-κB pathway (Jiang et al., 2008 ). FKBP5 was also described to influence radioresistance in melanoma cells (Romano et al., 2010) . Specifically, it was found that in melanoma samples FKBP51 controlled radioresistance through the activation of NF-κB pathway, and by silencing expression of FKBP5 in tumors in vitro and in vivo, it contributed to an increase in apoptosis after irradiation.
Prostate cancer
Note FKBP5 influences androgen receptor signaling in prostate cancer. Androgen receptor (AR) is a transcription factor, regulating expression of multiple genes, including FKBP5 (Makkonen et al., 2009) . Additionally, FKBP5 is a part of a positive feedback loop that not only is having its expression regulated by AR and androgen binding, but it also facilitates androgen-dependent transcription. Ni et al. (Ni et al., 2010) reported that FKBP5 forms a superchaperone complex with ATP-bound Hsp90 and p23 that increases binding of androgen to its receptor. This allows for androgen-dependent gene transcription activation and promotes cell growth, which is especially important during prostate cancer progression to the androgenindependent state during disease progression and tumor growth (Ni et al., 2010) .
Depression, post-traumatic stress disorder
Note It has been established that one of the major functions of FKBP51 is to co-chaperone with HSP family members steroid receptors: glucocorticoid (GR) (Denny et al., 2000) , progesterone (PR) (Barent et al., 1998) , and androgen (AR) (Ni et al., 2010) . In addition, FKBP5 intronic regions contain hormone response elements (HRE) that upon GR, PR, or AR activation bind their respective hormones. Figure 6 . Negative feedback loop on GR sensitivity. When HSP90-GR is bound to the FKBP51, it has a lower affinity for GR ligand (glucocorticoids). However, once glucocorticoids bind to the complex, FKBP51 dissociates from the complex and FKBP52 binds instead. That allows for the GR translocation into the nucleus and exertion of its action as a transcription factor. GR also acts on FKBP5 via its glucocorticoid response elements (GREs), increasing its transcription, which leads to an increase in amount of FKBP51 protein in the cell. That, in turn, decreases the GR affinity for its ligand, completing this negative feedback loop on GR sensitivity.
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